STALICLA announces closure of CHF 10M total for first tranche of series A

STALICLA is pleased to announce the successful closure of the 2018 tranche of its series A round for a total amount of CHF 10M committed by a consortium of private and Biotech experienced investors. This round of funding will be used to expand STALICLA’s team and advance the company’s first Autism personalized therapeutic package to clinical trials. Proceeds will also be used to scale-up STALICLA’s computational systems biology R&D unit which has recently been inaugurated in Barcelona, Spain.

STALICLA is excited to formally welcome its new shareholders.


STALICLA is an autism spectrum disorder (ASD) focused, data guided, drug development biotech company based in Geneva. Through an innovative algorithm-based platform (DEPI) STALICLA has been able to identify non-behavioral subgroups of patients with idiopathic ASD and corresponding first-in class treatment candidates, thus pioneering personalized medicines for ASD.


  • Q2 Second tranche of Series A
  • Q2 2019 Pre-IND meeting for STALICLA’s lead drug candidate STP1 with FDA
  • Q4 2019 IND submission
  • Early 2020 Clinical trials set to start
Back to News

Search for content on Stalicla...